Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Olivier T, Smith CEP, Haslam A, Addeo A, Prasad V. Quality of life in the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 to 2022. J Cancer Policy. 2023 Sep; 37:100426. PMID: 37270063
Smith CEP, Marcom PK, Mitri Z, Ko NY. Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions. Breast Cancer Res Treat. 2022 Nov; 196(1):215-220.View Related Profiles. PMID: 36087190; DOI: 10.1007/s10549-022-06718-w;
West MT, Smith CE, Kaempf A, Kohs TCL, Amirsoltani R, Ribkoff J, Choung JL, Palumbo A, Mitri Z, Shatzel JJ. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. Eur J Haematol. 2021 May; 106(5):634-642. PMID: 33527479; PMCID: PMC8087188; DOI: 10.1111/ejh.13590;
Smith CEP, Prasad V. Targeted Cancer Therapies. Am Fam Physician. 2021 02 01; 103(3):155-163. PMID: 33507053
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.